Liminatus Pharma (NASDAQ:LIMN – Get Free Report) released its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.
Liminatus Pharma Trading Down 2.2%
Shares of Liminatus Pharma stock opened at $0.18 on Friday. The firm has a market cap of $8.08 million and a P/E ratio of -1.20. Liminatus Pharma has a 12 month low of $0.16 and a 12 month high of $33.66. The stock’s fifty day moving average price is $0.20 and its 200-day moving average price is $0.61.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.
About Liminatus Pharma
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Read More
- Five stocks we like better than Liminatus Pharma
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
